Safety assessment of the Clostridium butyricum MIYAIRI 588 ® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Probiotics are live microorganisms ingested for the purpose of conferring a health benefit on the host. Development of new probiotics includes the need for safety evaluations that should consider factors such as pathogenicity, infectivity, virulence factors, toxicity, and metabolic activity. Clostridium butyricum MIYAIRI 588 ® (CBM 588 ® ), an anaerobic spore-forming bacterium, has been developed as a probiotic for use by humans and food animals. Safety studies of this probiotic strain have been conducted and include assessment of antimicrobial sensitivity, documentation of the lack of Clostridium toxin genes, and evaluation of CBM 588 ® on reproductive and developmental toxicity in a rodent model. With the exception of aminoglycosides, to which anaerobes are intrinsically resistant, CBM 588 ® showed sensitivity to all antibiotic classes important in human and animal therapeutics. In addition, analysis of the CBM 588 ® genome established the absence of genes for encoding for α, β, or ε toxins and botulin neurotoxins types A, B, E, or F. There were no deleterious reproductive and developmental effects observed in mice associated with the administration of CBM 588 ® . These data provide further support for the safety of CBM 588 ® for use as a probiotic in animals and humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The live bacterial product CBM588 contains Clostridium butyricum, a butyrate-producing anaerobic spore-forming bacterium13–15.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [15]
Citations
Cites
Nucleic acid techniques in bacterial systematics
Stackebrandt, E. S., & Goodfellow, M. (1991) · Wiley eBooks · Cited by 9,460
Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752 · cited 1×
“A recent study indicates that non-toxigenic Clostridium colonization may increase the percent and function of regulatory T cells in the colon and draining lymph nodes of mice.(13) However, several Clostridium species (i.”
BackgroundGuidelines for the evaluation of probiotics in food
Who, F. (2002) · Medical Entomology and Zoology · Cited by 1,843
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744 · cited 2×
“Colistin, also known as polymixin E, (MIC 1⁄4 >256 mg/L) is used intravenously, primarily as a drug of last resort in multidrug-resistant, Gram negative bacterial infections in the respiratory tract of cystic fibrosis patients.(35) The susceptibility of CBM 588(1) to clinically relevant antibiotics was also assessed (…”
BackgroundMethodA Note on the Staining of the Skeleton of Cleared Specimens with Alizarin Red S
Dawson, A. B. (1926) · Stain Technology · doi:10.3109/10520292609115636 · Cited by 1,041
Safety assessment of probiotics for human use
Sanders, M. E., Akkermans, L. M. A., Haller, D., Hammerman, C., Heimbach, J. T., Hörmannsperger, G., & Huys, G. (2010) · Gut Microbes · doi:10.4161/gmic.1.3.12127 · Cited by 816
Probiotics: Definition, Sources, Selection, and Uses
Sanders, M. E. (2008) · Clinical Infectious Diseases · doi:10.1086/523341 · Cited by 661 · cited 1×
“Probiotics are defined internationally as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.(1) The safety in use of many probiotics has been extensively studied and documented.”
BackgroundMolecular genetics and pathogenesis of Clostridium perfringens
Rood, J. I., & Cole, S. T. (1991) · Microbiological Reviews · doi:10.1128/mmbr.55.4.621-648.1991 · Cited by 450 · cited 1×
“perfringens include a, , and " toxins.(15) In addition, the highly potent botulinum neurotoxins (BoNT), the causative agent in all cases of botulism(16) are known to be produced by many Clostridium species.”
BackgroundGenetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains
Hill, K. K., Smith, T. J., Helma, C. H., Ticknor, L. O., Foley, B. T., Svensson, R. T., Brown, J. L., Johnson, E. A., Smith, L. A., Okinaka, R. T., et al. (2007) · Journal of Bacteriology · doi:10.1128/jb.01180-06 · Cited by 379
Clostridium botulinum neurotoxin
Sugiyama, H. (1980) · Microbiological Reviews · doi:10.1128/mmbr.44.3.419-448.1980 · Cited by 336
Research works printed but not linked: 16
- Pattani R, 2013, Open Med, 7, e56
- Barkay T, 2005, ASM News, 71, 412
- 10.1128/mr.55.4.621-648.1991 · doi:10.1128/mr.55.4.621-648.1991 · Paper page
- EU. Commission Regulation (EC) No 903/2009 of 28 September 2009 concerning the authorisation of the preparation of Clostridium butyricum MIYAIRI 588 (FERM-P 1467) as a feed additive for chickens for fattening (holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Mitsui & Co. Deutschland GmbH). Official Journal of the European Union L02/10, http://eur-lex.europa.eu (2009, accessed 1 April 2015).
- EU. Commission Implementing Regulation (EU) No 373/2011 of 15 April 2011 concerning the authorisation of the preparation of Clostridium butyricum FERM-BP 2789 as a feed additive for minor avian species except laying birds, weaned piglets and minor porcine species (weaned) and amending Regulation (EC) No 903/2009 (holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U.). Official Journal of the European Union L02/10, http://eur-lex.europa.eu (2011, accessed 1 April 2015).
- EU. Commission Implementing Regulation (EU) No 1108/2014 of 20 October 2014 concerning the authorisation of a preparation of Clostridium butyricum (FERM BP-2789) as a feed additive for turkeys for fattening and turkeys reared for breeding (holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.). Official Journal of the European Union L301/16, http://eur-lex.europa.eu (2014, accessed 1 April 2015).
- EU. Commission Implementing Decision of 11 December 2014 authorising the placing on the market of Clostridium butyricum (CBM 588) as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council. Official Journal of the European Union L359/153, http://eur-lex.europa.eu (2014, accessed 1 April 2015).
- Yuzawa T, 1987, Pharmacometrics, 34, 215
- Yuzawa T, 1987, Pharmacometrics, 34, 223
- Yuzawa T, 1987, Pharmacometrics, 33, 683
- CLSI, 2012, Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard – eighth edition. CLSI document M11-A8
- CLSI, 2012, Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second informational Supplement. CLSI document M100-S22
- Japan Ministry of Health and Welfare, Pharmaceutical guidelines for teratogenicity and reproductive toxicity studies
- EFSA, 2012, EFSA J, 10, 2740
- EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), 2009, EFSA J, 1039, 1
- Wang W, 2000, Jpn Pharmacol Ther, 28, 999
Cited by
Next-generation probiotics: the spectrum from probiotics to live biotherapeutics
O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.57 · Cited by 971
Butyrate-producing human gut symbiont, Clostridium butyricum , and its role in health and disease
Stoeva, M. K., Garcia-So, J., Justice, N., Myers, J., Tyagi, S., Nemchek, M., McMurdie, P. J., Kolterman, O., & Eid, J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1907272 · Cited by 518
“studies have shown that it is sensitive to antibiotics, devoid of pathogenic markers, and lacks clostridial toxin genes.(11) Dysbiosis in the gut microbiome has been implicated in multiple diseases, including gastrointestinal, neurological, and metabolic disorders, as well as cancer.”
BackgroundDizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515
Self-citationModulation of bone remodeling by the gut microbiota: A new therapy for osteoporosis
Lyu, Z., Hu, Y., Guo, Y., & Liu, D. (2023) · Bone Research · doi:10.1038/s41413-023-00264-x · Cited by 207
Brodmann, T., Endo, A., Gueimonde, M., Vinderola, G., Kneifel, W., de Vos, W. M., Salminen, S., & Gómez-Gallego, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01725 · Cited by 191
“An antibiotic resistance profile, a study for genes encoding toxins, and an animal study were conducted to ensure the safety of the strain (Isa et al., 2016).”
Background
Metadata
- Authors
- Isa, K., Oka, K., Beauchamp, N., Sato, M., Wada, K., Ohtani, K., Nakanishi, S., McCartney, E., Tanaka, M., Shimizu, T., Kamiya, S., Kruger, C., & Takahashi, M.
- Affiliations
- Miyarisan Pharmaceutical Co., Ltd. (Japan) (JP)
- Spherix Consulting, Rockville, MD, USA
- Kanazawa University (JP)
- Pen & Tec Consulting, Barcelona, Spain
- Kyorin University (JP)
- Corresponding author
- Takahashi, M
- Venue
- Human & Experimental Toxicology
- Publisher
- SAGE Publications
- Published
- 2016-07-20
- Volume
- 35
- Issue
- 8
- Pages
- 818-832
- ISSN
- 0960-3271 (ISSN-L)
- 1477-0903
- OpenAlex
- W2267159929
- Cited by
- 52
- References
- 45
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 7 · 2021: 5 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 1
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Human & Experimental Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Miyarisan Pharmaceutical
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Agricultural and Biological Sciences › Food Science › Agricultural safety and regulations
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Keywords
- probiotic safety, antimicrobial susceptibility, botulinum toxin, reproductive toxicity, developmental toxicity, teratogenicity, anaerobic spore-forming bacteria, aminoglycoside resistance
- MeSH terms
- Abnormalities, Drug-Induced, Animals, Anti-Bacterial Agents, Bacterial Toxins, Botulinum Toxins, Enterotoxins, Female, Male, Mice, Inbred ICR, Microbial Sensitivity Tests, Neurotoxins, Pregnancy, Reproduction, Probiotics, Drug Resistance, Bacterial, Clostridium butyricum, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety assessment of the Clostridium butyricum MIYAIRI 588 ® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo. https://app.cochat.ai/papers/10.1177/0960327115607372
- The paper
- Isa, K., Oka, K., Beauchamp, N., Sato, M., Wada, K., Ohtani, K., Nakanishi, S., McCartney, E., Tanaka, M., Shimizu, T., Kamiya, S., Kruger, C., & Takahashi, M. (2016). Safety assessment of the Clostridium butyricum MIYAIRI 588 ® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo. Human & Experimental Toxicology. https://doi.org/10.1177/0960327115607372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.